Forum: Galapagos » Galapagos september 2019 | Eurobench.com

Galapagos september 2019

1.605 Posts, Pagina: « 1 2 3 4 5 6 ... 76 77 78 79 80 81 | Laatste
Aantal posts per pagina:  20 50 100 | Omlaag ↓
Endless
1
JPMorgan Chase & Co. Boosts Stake in GALAPAGOS NV/S (NASDAQ:GLPG)
Sunday, September 15th, 2019
Janice Underwood

JPMorgan Chase & Co. increased its position in GALAPAGOS NV/S (NASDAQ:GLPG) by 464.1% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 24,790 shares of the biotechnology company’s stock after purchasing an additional 20,395 shares during the period. JPMorgan Chase & Co.’s holdings in GALAPAGOS NV/S were worth $3,162,000 at the end of the most recent quarter.
Several other institutional investors have also recently bought and sold shares of the company. FMR LLC lifted its holdings in shares of GALAPAGOS NV/S by 35.3% in the 1st quarter. FMR LLC now owns 502,193 shares of the biotechnology company’s stock valued at $59,148,000 after purchasing an additional 131,119 shares during the last quarter. Bessemer Group Inc. purchased a new stake in shares of GALAPAGOS NV/S in the 2nd quarter valued at about $48,447,000. Marshall Wace North America L.P. lifted its holdings in shares of GALAPAGOS NV/S by 149.4% in the 1st quarter. Marshall Wace North America L.P. now owns 18,751 shares of the biotechnology company’s stock valued at $2,208,000 after purchasing an additional 11,233 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its holdings in shares of GALAPAGOS NV/S by 121.4% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 6,200 shares of the biotechnology company’s stock valued at $632,000 after purchasing an additional 3,400 shares during the last quarter. Finally, Pinnacle Associates Ltd. lifted its holdings in shares of GALAPAGOS NV/S by 128.9% in the 2nd quarter. Pinnacle Associates Ltd. now owns 4,484 shares of the biotechnology company’s stock valued at $578,000 after purchasing an additional 2,525 shares during the last quarter. 16.67% of the stock is owned by institutional investors and hedge funds.
Several analysts have recently weighed in on the company. BidaskClub downgraded GALAPAGOS NV/S from a “strong-buy” rating to a “buy” rating in a report on Friday, September 6th. Cowen reissued a “buy” rating on shares of GALAPAGOS NV/S in a report on Friday, July 26th. Jefferies Financial Group downgraded GALAPAGOS NV/S from a “buy” rating to a “hold” rating in a report on Monday, July 29th. Nomura boosted their target price on GALAPAGOS NV/S from $140.00 to $209.00 and gave the company a “buy” rating in a report on Monday, July 29th. Finally, Stifel Nicolaus boosted their target price on GALAPAGOS NV/S from $121.00 to $188.00 and gave the company a “buy” rating in a report on Monday, July 15th. Two analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $167.90.

Shares of GLPG stock opened at $161.16 on Friday. GALAPAGOS NV/S has a 52-week low of $85.00 and a 52-week high of $191.63. The stock’s 50-day moving average price is $170.20 and its 200 day moving average price is $132.72. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.40 and a current ratio of 6.40.
Endless
0
GALAPAGOS NV/S (NASDAQ:GLPG) last issued its quarterly earnings results on Thursday, July 25th. The biotechnology company reported ($0.97) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by ($0.13). The company had revenue of $75.96 million during the quarter, compared to analyst estimates of $56.66 million. GALAPAGOS NV/S had a negative net margin of 19.95% and a negative return on equity of 5.45%. As a group, equities research analysts anticipate that GALAPAGOS NV/S will post 5.17 EPS for the current year.

GALAPAGOS NV/S Company Profile

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
pardon
0
Een winst van 5,17 $ per aandeel in 2019 moet toch wat investeerders wakker schudden zou ik zeggen,na verkoop van de eerste pillen in 2020 moet dan toch zeker 10 euro winst worden gemaakt lijkt mij.
Fiero1985
0
quote:

djyves schreef op 15 sep 2019 om 18:57:


is een koers 160 haalbaar deze week? Graag uw mening


Nee, een koers van 140-145 wel maar de 160 zeker niet.
pe26
2
quote:

Fiero1985 schreef op 16 sep 2019 om 00:25:


[...]

Nee, een koers van 140-145 wel maar de 160 zeker niet.




en 150? en 155?

De kans dat er nieuws komt vanuit Galapagos NV wordt elke dag groter, en dat maakt het voorspellen van de koers niet te doen.

Bij sterke fase 2 data in Sjogren's gaan de radars anders draaien, want Filgotinib zal daarna in beeld blijven met bijkomstig positieve newsflow.

1.605 Posts, Pagina: « 1 2 3 4 5 6 ... 76 77 78 79 80 81 | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 13-sep-19 17:35
Koers 146,800
Verschil 0,000 (0,00%)
Hoog 146,800
Laag 143,250
Volume 220.573
Volume gemiddeld 323.509
Volume gisteren 220.573